CS MEDICA A/S: CS MEDICA Closes 1.1 MDKK White-Label CBD-Infused Product Order for Italy
Launch in Italy Planned for Q2 2025, with Global Expansion to Follow
CS MEDICA, a Danish MedTech company and leader in CBD-infused medical devices, announces its subsidiary CANNORDIC signed a new white-label partnership, marking a milestone in its expansion strategy. The collaboration, initiated at the CPHI Worldwide event in Milan, focuses on MDR-compliant products. The first order, valued at 1.1 million DKK, includes Pain & Arthritis Gel and Wound Gel, set for launch in Italy in Q2 2025. The initial launch in Italy will leverage the partner's extensive network, with plans to target pharmacies with their own brand.
MDR Compliance: A Key Differentiator
CS MEDICA's advanced MDR compliance was crucial in securing this partnership. The selected products are confirmed MDR Class IIa and are in the final stages of reclassification, bridging the gap between pharmaceutical and CBD-infused self-care solutions.
Launch Plans and Future Expansion
Discussions continue regarding future product additions and global distribution to over 50 countries. For competitive reasons, the brand and rollout details will be disclosed at the time of launch.